Rezera Announces Positive RESOLVE-2 Phase 2 Clinical Trial Results Demonstrating FavorableSafety and Tolerability Profile for Ruvonoflast in Combination with Semaglutide
October 7, 2026
Combination of ruvonoflast and semaglutide produced greater reductions in hsCRP versussemaglutide monotherapy Boston, MA, October 7, 2026 – Rezera Inc. (the “Company”), a clinical-stage biotechnology